Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie
Title :
Wytyczne ESC dotyczace cukrzycy, stanu przedcukrzycowego i chorob ukladu sercowo-naczyniowego opracowane we wspolpracy z EASD.
International Diabetes Federation 2011. Global Burden: Prevalence and Projections, 2011 and 2030. Available from http://www.diabetesatlas.org/content/ diabetes-and-impairedglucose-tolerance.
WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999. Report no. 99.2. http://whqlibdoc.who.int/hq/1999/who-ncd-ncs-99.2.pdf.
World Health Organization (WHO) Consultation. Definition and diagnosis of diabetes and intermediate hyperglycaemia. 2006. http:////www.who.int/diabetes/ publications/Definition%20and%20diagnosis%20of%20diabetes-new.pdf.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997; 20: 1183-1197.
Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26: 3160-3167.
Diagnosis and classification of diabetes mellitus. Diabetes Care, 2012; 35 (suppl. 1): S64-S71.
World Health Organization (WHO), Abbreviated report of aWHO Consultation. Use of glycated hemoglobin (HbA1c) in the diagnosis if diabetes mellitus. 2011. http://www.who.int/diabetes/publications/diagnosis-diabetes2011/en/index.html.
Diagnosis and classification of diabetes mellitus. Diabetes Care, 2010; 33 (suppl. 1): S62-S69.
Costa B, Barrio F, Cabre JJ et al. Shifting from glucose diagnostic criteria to the new HbA(1c) criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population. Diabet Med, 2011; 28: 1234-1237.
Pajunen P, Peltonen M, Eriksson JG et al. HbA(1c) in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabet Med, 2011; 28: 36-42.
Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes Care, 1985; 8: 114-117.
Gottsater A, Landin-Olsson M, Fernlund P et al. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care, 1993; 16: 902-910.
Tuomilehto J, Zimmet P, Mackay IR et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet, 1994; 343: 1383-1385.
Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med, 2006; 23: 857-866.
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia, 2003; 46: 3-19.
Mari A, Tura A, Natali A et al. Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia, 2010; 53: 749-756.
Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet, 2009; 373: 1773-1779.
Feig DS, Zinman B,Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ: Canadian Medical Association journal LJournal de l'Association Medicale Canadienne, 2008; 179: 229-234.
Carstensen B, Lindstrom J, Sundvall J et al. Measurement of blood glucose: comparison between different types of specimens. Ann Clin Biochem, 2008; 45 (part 2): 140-148.
Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care, 2003; 26: 61-69.
Christensen DL, Witte DR, Kaduka L et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care, 2010; 33: 580-582.
Colagiuri S, Lee CM, Wong TY et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care, 2011; 34: 145-150.
Pani LN, Korenda L, Meigs JB et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care, 2008; 31: 1991-1996.
Saaristo TE, Barengo NC, Korpi-Hyovalti E et al. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. BMC Public Health, 2008; 8: 423.
Engelgau MM, Colagiuri S, Ramachandran A et al. Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. Diabetes Technol Ther, 2004; 6: 874-882.
Griffin SJ, Borch-Johnsen K, Davies MJ et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet, 2011; 378: 156-167.
Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2001; 344: 1343-1350.
Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002; 346: 393-403.
Roumen C, Corpeleijn E, Feskens EJ et al. Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet Med, 2008; 25: 597-605.
Penn L, White M, Oldroyd J et al. Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health, 2009; 9: 342.
Gillies CL, Abrams KR, Lambert PC et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ, 2007; 334: 299-308.
Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of haemoglobin A(1c). J Intern Med, 2011.
Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Human Reproduction, 2013.
Zhou X, Pang Z, Gao W et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care, 2010; 33: 545-550.
Abbasi A, Peelen LM, Corpeleijn E et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ, 2012; 345: e5900.
Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care, 2003; 26: 725-731.
Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res, 2009; 41: 86-97.
Bartnik M, Ryden L, Malmberg K et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart, 2007; 93: 72-77.
Hage C, Lundman P, Ryden L, Mellbin L. Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes. Eur J Prev Cardiol, 2012.
de Mulder M, Oemrawsingh RM, Stam F et al. Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. Heart, 2012; 98: 37-41.
Doerr R, Hoffmann U, Otter W et al. Oral glucose tolerance test and HbA(1)c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study. Diabetologia, 2011; 54: 2923-2930.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 1999; 354: 617-621.
The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care, 2003; 26: 688-696.
Ning F, Tuomilehto J, Pyorala K et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care, 2010; 33: 2211-2216.
Khaw KT, Wareham N, Bingham S et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med, 2004; 141: 413-420.
Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes and cardiovascular risk in nondiabetic adults. N Engl J Med, 2010; 362: 800-811.
Santos-Oliveira R, Purdy C, da Silva MP et al. Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia, 2011; 54: 1327-1334.
Qiao Q, Dekker JM, de Vegt F et al. Two prospective studies found that elevated 2-hr glucose predictedmale mortality independent of fasting glucose and HbA1c. J Clin Epidemiol, 2004; 57: 590-596.
Meigs JB, Nathan DM, D'Agostino RB Sr., Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care, 2002; 25: 1845-1850.
Barrett-Connor EL, CohnBA, Wingard DL, Edelstein SL.Whyis diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA, 1991; 265: 627-631.
Juutilainen A, Kortelainen S, Lehto S et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care, 2004; 27: 2898-2904.
Hu G, Jousilahti P, Qiao Q et al. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol, 2005; 45: 1413-1418.
Orchard TJ. The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med, 1996; 28: 323-333.
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ, 2006; 332: 73-78.
Wannamethee SG, Papacosta O, Lawlor DA et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia, 2012; 55: 80-87.
Logue J, Walker JJ, Colhoun HM et al. Domen develop type 2 diabetes at lower body mass indices than women? Diabetologia, 2011; 54: 3003-3006.
Mann JI, De Leeuw I, Hermansen K et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis, 2004; 14: 373-394.
Burr JF, Rowan CP, Jamnik VK, Riddell MC. The role of physical activity in type 2 diabetes prevention: physiological and practical perspectives. Phys Sportsmed, 2010; 38: 72-82.
Paulweber B, Valensi P, Lindstrom J et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res, 2010; 42 (suppl. 1): S3-36.
Lindstrom J, Neumann A, Sheppard KE et al. Take action to prevent diabetes: the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res, 2010; 42 (suppl. 1): S37-S55.
Eriksson KF, Lindgarde F. Noexcess 12-year mortality inmenwith impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia, 1998; 41: 1010-1016.
Li G, Zhang P, Wang J et al. The longterm effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet, 2008; 371: 1783-1789.
Gong Q, Gregg EW, Wang J et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia, 2011; 54: 300-307.
Uusitupa M, Peltonen M, Lindstrom J et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study: secondary analysis of the randomized trial. PLoS One, 2009; 4: e5656.
Knowler WC, Fowler SE, Hamman RF et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet, 2009; 374: 1677-1686.
Saito T, Watanabe M, Nishida J et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med, 2011; 171: 1352-1360.
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med, 2007; 356: 213-215.
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 2001; 414: 799-806.
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 2006; 113: 1888-1904.
Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest, 1996; 98: 894-898.
Flammer AJ, Anderson T, Celermajer DS et al. The assessment of endothelial function: from research into clinical practice. Circulation, 2012; 126: 753-767.
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic reviewand meta-analysis. J Am Coll Cardiol, 2010; 55: 1318-1327.
Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation, 1997; 96: 25-28.
Paneni F, Mocharla P, Akhmedov A et al. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circulation Research, 2012; 111: 278-289.
Cosentino F, Eto M, De Paolis P et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation, 2003; 107: 1017-1023.
Camici GG, Schiavoni M, Francia P et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci USA, 2007; 104: 5217-5222.
Cosentino F, Francia P, Camici GG et al. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc prot. Arterioscler Thromb Vasc Biol, 2008; 28: 622-628.
Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab, 2009; 94: 410-415.
Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance and roles of inflammation: mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol, 2012; 32: 1771-1776.
Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus and cardiovascular disease: clinical implications. Am J Cardiol, 2008; 102: 5L-9L.
Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 2010; 121: 110-122.
Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med, 2007; 262: 157-172.
Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation, 2011; 123: 798-813.
Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care, 2003; 26: 2791-2795.
Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res, 2006; 98: 596-605.
Clark RJ, McDonough PM, Swanson E et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem, 2003; 278: 44230-44237.
Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120: 1640-1645.
Jarajapu YP, Grant MB. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res, 2010; 106: 854-869.
Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 2012; 33: 1635-1701.
Anderson KM, Odell PM, WilsonPW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J, 1991; 121: 293-298.
D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA, 2001; 286: 180-187.
Ramachandran S, French JM, Vanderpump MP, Croft P, Neary RH. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ, 2000; 320: 676-677.
Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care, 2007; 30: 1292-1293.
Jimeno Mollet J, Molist Brunet N, Franch Nadal J et al. [Variability in the calculation of coronary risk in type-2 diabetes mellitus]. Aten Primaria, 2005; 35: 30-36.
Pencina MJ, D'Agostino RB Sr., Larson MG et al. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation, 2009; 119: 3078-3084.
Balkau B, Hu G, Qiao Q et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia, 2004; 47: 2118-2128.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation, 2002; 105: 310-315.
Stephens JW, Ambler G, Vallance P et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil, 2004; 11: 521-528.
Marrugat J, Solanas P, D'Agostino R et al. (Coronary risk estimation in Spain using a calibrated Framingham function). Rev Esp Cardiol, 2003; 56: 253-261.
Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care, 1999; 22: 1667-1671.
Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond), 2001; 101: 671-679.
Guzder RN, Gatling W, Mullee MA et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med, 2005; 22: 554-562.
Protopsaltis ID, Konstantinopoulos PA, Kamaratos AV, Melidonis AI. Comparative study of prognostic value for coronary disease risk between the U.K. prospective diabetes study and Framingham models. Diabetes Care, 2004; 27: 277-278.
Cederholm J, Eeg-Olofsson K, Eliasson B et al. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care, 2008; 31: 2038-2043.
D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke, 1994; 25: 40-43.
Costa B, Cabre JJ, Martin F et al. [The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population]. Aten Primaria, 2005; 35: 392-398.
Kothari V, Stevens RJ, Adler AI et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 2002; 33: 1776-1781.
Kengne AP, Patel A, Marre M et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil, 2011; 18: 393-398.
Chamnan P, Simmons RK, Sharp SJ et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia, 2009; 52: 2001-2014.
Folsom AR, Chambless LE, Ballantyne CM et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med, 2006; 166: 1368-1373.
Meerwaldt R, Graaff R, Oomen PH et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia, 2004; 47: 1324-1330.
Lutgers HL, Gerrits EG, Graaff R et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia, 2009; 52: 789-797.
Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA, 2001; 286: 421-426.
Gaede P, Hildebrandt P, Hess G et al. Plasma N-terminal probrain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia, 2005; 48: 156-163.
Anand DV, Lim E, Hopkins D et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J, 2006; 27: 713-721.
Hanssen NM, Huijberts MS, Schalkwijk CG et al. Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2diabetes: nineteen-year follow-up of a population-based cohort study. Diabetes Care, 2012; 35: 1731-1735.
Bernard S, Serusclat A, Targe F et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care, 2005; 28: 1158-1162.
Cruickshank K, Riste L, Anderson SG et al. Aortic pulsewave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation, 2002; 106: 2085-2090.
Pop-Busui R, Evans GW, Gerstein HC et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 2010; 33: 1578-1584.
Valensi P, Lorgis L, CottinY. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis, 2011; 104: 178-188.
Cosson E, Nguyen MT, Chanu B et al. Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. Diabetes Care, 2011; 34: 2101-2107.
Young LH, Wackers FJ, Chyun DA et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA, 2009; 301: 1547-1555.
Gazzaruso C, Coppola A, Montalcini T et al. Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients. Intern Emerg Med, 2012; 7: 257-266.
Marwick TH, Hordern MD, Miller T et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation, 2009; 119: 3244-3262.
Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32: 1769-1818.
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012; 55: 1577-1596.
NICE Type 2 diabetes: the management of type 2 diabetes: NICE Clinical Guideline 87: National Institute for Health and Clinical Excellence 2009.
Nield L, Moore HJ, Hooper L et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev, 2007; 3: CD004097.
Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care, 2008; 31 (suppl. 1):S61-78.
Executive summary: Standards of medical care in diabetes: 2013. Diabetes Care, 2013; 36 (suppl. 1): S4-S10.
Pi-Sunyer X, Blackburn G, Brancati FL et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2diabetes: one-year results of the look AHEAD trial. Diabetes Care, 2007; 30: 1374-1383.
Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med, 2010; 170: 1566-1575.
Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med, 2004; 351: 2683-2693.
Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein and carbohydrates. N Engl J Med, 2009; 360: 859-873.
Hamer M, Chida Y. Intake of fruit, vegetables and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis. J Hypertens, 2007; 25: 2361-2369.
Estruch R, Ros E, Salas-Salvado J et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Eng J Med, February 25, 2013.
Nothlings U, Ford ES, Kroger J, Boeing H. Lifestyle factors and mortality among adults with diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam study*. Journal of Diabetes, 2010; 2: 112-117.
Bidel S, Hu G, Qiao Q et al. Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes. Diabetologia, 2006; 49: 2618-2626.
Jee SH, He J, Appel LJ et al. Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol, 2001; 153: 353-362.
Colberg SR, Sigal RJ, Fernhall B et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care, 2010; 33: 2692-2696.
Sluik D, Buijsse B, Muckelbauer R et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis. Arch Intern Med, 2012; 172: 1285-1295.
Vanhees L, Geladas N, Hansen D et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol, 2012; 19: 1005-1033.
Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care, 2006; 29: 2518-2527.
Umpierre D, Ribeiro PA, Kramer CK et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA, 2011; 305: 1790-1709.
Kirk AF, Barnett J, Mutrie N. Physical activity consultation for people with Type 2 diabetes: evidence and guidelines. Diabet Med, 2007; 24: 809-816.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405-412.
Sigal RJ, Kenny GP, Boule NG et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med, 2007; 147: 357-369.
Willi C, Bodenmann P, Ghali WA et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 2007; 298: 2654-2664.
Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet, 2003; 362: 847-852.
Brunnhuber K, Cummings K, Feit S et al. Putting evidence into practice: Smoking cessation BMJ Group 2007.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 1993; 329: 977-986.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352: 837-853.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352: 854-865.
Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353: 2643-2653.
Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577-1589.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358: 580-591.
Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine and the International Diabetes Federation. Diabetes Care, 2007; 30: 2399-2400.
Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 2003; 63: 225-232.
Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358: 2545-2559.
Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008; 358: 2560-2572.
Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009; 360: 129-139.
Hemmingsen B, Lund SS, Gluud C et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ, 2011; 343: d6898.
The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes, 1996; 45: 1289-1298.
Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Ametaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care, 1999; 22: 233-240.
Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010; 375: 2215-2222.
Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ, 2010; 340: b4909.
Gerstein HC, Miller ME, Genuth S et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Eng J Med, 2011; 364: 818-828.
Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Eng J Med, 2012; 367: 319-328.
Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009; 52: 2288-2298.
Farmer AJ, Wade AN, French DP et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technol Assess 2009; 13: iii-iv, ix-xi, 1-50.
Cavalot F, Pagliarino A, Valle M et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care, 2011; 34: 2237-2243.
Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 2003; 290: 486-494.
Raz I, Wilson PW, Strojek K et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care, 2009; 32: 381-386.
Raz I, Ceriello A, Wilson PW et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care, 2011; 34: 1511-1513.
Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005; 366: 1279-1289.
Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2006; 1: CD002967.
Holstein A, Stumvoll M. Contraindications can damage your health: is metformin a case in point? Diabetologia, 2005; 48: 2454-2459.
Nissen SE,Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007; 356: 2457-2471.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab, 2011; 13: 221-228.
Holman RR, Haffner SM, McMurray JJ et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010; 362: 1463-1476.
Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab, 2010; 36 (suppl. 3): S64-S74.
Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care, 2011; 34 (suppl. 2): S132-S137.
Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab, 2005; 7: 493-503.
Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab, 2011; 12: 57-69.
Cleary PA, Orchard TJ, Genuth S et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2006; 55: 3556-3565.
Soedamah-Muthu SS, Colhoun HM, Abrahamian H et al. Trends in hypertension management in type I diabetes across Europe, 1989/1990-1997/1999. Diabetologia, 2002; 45: 1362-1371.
Nilsson PM, Cederholm J, Zethelius BR et al. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press, 2011; 20: 348-354.
Redon J, Cifkova R, Laurent S et al. Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens, 2009; 27: 441-451.
Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl, 2003; 21: S25-S30.
Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998; 317: 703-713.
Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1575-1585.
Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007; 370: 829-840.
Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med, 2008; 359: 1565-1576.
Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998; 351: 1755-1762.
Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 2000; 321: 412-419.
Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation, 2011; 123: 2799-2810.
Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 1998; 21: 597-603.
Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med, 1998; 338: 645-652.
Niskanen L, Hedner T, Hansson L et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care, 2001; 24: 2091-2096.
Lindholm LH, Hansson L, Ekbom T et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens, 2000; 18: 1671-1675.
Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet, 2000; 356: 359-365.
Mancia G, Brown M, Castaigne A et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 2003; 41: 431-436.
Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med, 2005; 165: 1401-1409.
Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002; 359: 1004-1010.
Ostergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressurelowering limb: effects in patients with type II diabetes. J Hypertens, 2008; 26: 2103-2111.
Weber MA, Bakris GL, Jamerson K et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol, 2010; 56: 77-85.
Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 2004; 351: 1941-1951.
Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Eng J Med, 2012; 367: 2204-2213.
Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547-1559.
Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther, 2009; 7: 1349-1361.
Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med, 2005; 165: 1410-1419.
Anselmino M, Malmberg K, Ohrvik J, Ryden L. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil, 2008; 15: 216-223.
Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertensionmanagement: a European Society of Hypertension Task Force document. J Hypertens, 2009; 27: 2121-2158.
2013 ESH/ESC Guidelines for the management of arterial hypertension 10.1093/eurheartj/eht151. Eur Heart J, 2013.
Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008; 28: 1225-1236.
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology, 2010; 51: 679-689.
Taskinen MR, Adiels M, Westerbacka J et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol, 2011; 31: 2144-2150.
McQuaid SE, Hodson L, Neville MJ et al. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes, 2011; 60: 47-55.
Kotseva K, Stagmo M, De Bacquer D et al. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis, 2008; 197: 710-717.
Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil, 2009; 16: 121-137.
Eriksson M, Zethelius B, Eeg-Olofsson K et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil, 2011; 18: 97-105.
Eliasson B, Svensson AM, Miftaraj M et al. Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus: an observational study from the Swedish National Diabetes Register. PLoS One, 2011; 6: e18744.
Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361.
Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333.
Barter P, Gotto AM, LaRosa JC et al. HDLcholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med, 2007; 357: 1301-1310.
Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681.
Scott R, O'Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 2009; 32: 493-498.
Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574.
Taskinen MR, Barter PJ, Ehnholm C et al. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 2010; 53: 1846-1855.
Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins and risk of vascular disease. JAMA, 2009; 302: 1993-2000.
Mills EJ, O'Regan C, Eyawo O et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of 40 000 patients. Eur Heart J, 2011; 32: 1409-1415.
Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278.
Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 2008; 371: 117-125.
Cannon CP, Steinberg BA, Murphy SA et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol, 2006; 48: 438-445.
Nicholls SJ, Tuzcu EM, Kalidindi S et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol, 2008; 52: 255-262.
Leiter LA, Betteridge DJ, Farnier M et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab, 2011; 13: 615-628.
Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet, 2004; 364: 685-696.
Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2003; 361: 2005-2016.
Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm (ASCOT-LLA). Diabetes Care, 2005; 28: 1151-1157.
Armitage J. The safety of statins in clinical practice. Lancet, 2007; 370: 1781-1790.
Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011; 217 (suppl. 1): S1-S44.
Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735-742.
Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 2011; 305: 2556-2564.
Cannon CP. Balancing the benefits of statins versus a new risk-diabetes. Lancet, 2010; 375: 700-701.
Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012; 380: 581-590.
Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861.
Bruckert E, Labreuche J, Deplanque D et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol, 2011; 57: 267-272.
Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic reviewand meta-analysis. Lancet, 2010; 375: 1875-1884.
Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Eng J Med, 2007; 357: 2109-2122.
Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Eng J Med, 2012; 367: 2089-2099.
Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther, 2010; 126: 314-345.
Lee JM, Robson MD, Yu LM et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol, 2009; 54: 1787-1794.
Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267.
HPS2-THRIVE. www.Thrivestudy.org (21 August 2013).
Preiss D, Tikkanen MJ, Welsh P et al. Lipidmodifying therapies and risk of pancreatitis: a meta-analysis. JAMA, 2012; 308: 804-811.
Fruchart JC, Sacks FM, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res, 2008; 5: 319-335.
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med, 2007; 357: 2482-2494.
Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost, 2004; 2: 1282-1291.
Santilli F, Formoso G, Sbraccia P et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost, 2010; 8: 828-837.
Davi G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med, 1990; 322: 1769-1774.
Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005; 353: 2373-2383.
Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association and an expert consensus document of the American College of Cardiology Foundation. Circulation, 2010; 121: 2694-2701.
Pulcinelli FM, Biasucci LM, Riondino S et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J, 2009; 30: 1279-1286.
DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 2007; 56: 3014-3019.
Evangelista V, de Berardis G, Totani L et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost, 2007; 5: 2197-2203.
Rocca B, Santilli F, Pitocco D et al. The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. J Thromb Haemost, 2012; 10: 1220-1230.
Dillinger JG, Drissa A, Sideris G et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J, 2012; 164: 600-606 e1.
Collaborative overview of randomised trials of antiplatelet therapy: I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ, 1994; 308: 81-106.
Rosenzweig JL, Ferrannini E, Grundy SM et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008; 93: 3671-3689.
Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 2008; 337: a1840.
Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008; 300: 2134-2141.
Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009; 373: 1849-1860.
Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med, 2006; 4: 22.
Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J, 2011; 32: 2922-2932.
Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996; 348: 1329-1339.
Dasgupta A, Steinhubl SR, Bhatt DL et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance [CHARISMA] trial). Am J Cardiol, 2009; 103: 1359-1363.
Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med, 2007; 357: 2001-2015.
Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomesby optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation, 2008; 118: 1626-1636.
Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med, 2009; 361: 1045-1057.
James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J, 2010; 31: 3006-3016.
James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2010; 122: 1056-1067.
Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345: 494-502.
Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol, 2002; 90: 625-628.
Ng AC, Delgado V, Djaberi R et al. Multimodality imaging in diabetic heart disease. Curr Probl Cardiol, 2011; 36: 9-47.
van Dieren S, Peelen LM, Nothlings U et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia, 2011; 54: 264-270.
Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screendetected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract, 2009; 59: 43-48.
Simmons RK, Sharp SJ, Sandbaek A et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe clusterrandomized trial. Diabet Med, 2012; 29: e409-e416.
Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet, 1999; 353: 617-622.
Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003; 348: 383-393.
Gaede P, Valentine WJ, Palmer AJ et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care, 2008; 31: 1510-1515.
Abbasi F, Chen YD, Farin HM et al. Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. Am J Cardiol, 2008; 102: 64-69.
Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, 2002; 359: 2140-2144.
Bartnik M, Ryden L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J, 2004; 25: 1880-1890.
Lenzen M, Ryden L, Ohrvik J et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J, 2006; 27: 2969-2974.
Bartnik M, Malmberg K, Norhammar A et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J, 2004; 25: 1990-1997.
Meisinger C, Heier M, von Scheidt W et al. Gender-Specific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA/KORA Myocardial Infarction Registry). Am J Cardiol, 2010; 106: 1680-1684.
International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care, 2009; 32: 1327-1334.
Tenerz A, Norhammar A, Silveira A et al. Diabetes, insulin resistance and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care, 2003; 26: 2770-2776.
Opie LH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation, 2008; 117: 2172-2177.
Franklin K, Goldberg RJ, Spencer F et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med, 2004; 164: 1457-1463.
Norhammar A, Malmberg K, Diderholm E et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol, 2004; 43: 585-591.
Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007; 28: 1598-1660.
Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J, 2006; 27: 1341-1381.
Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 2999-3054.
Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012; 33: 2569-2619.
Wijns W, Kolh P, Danchin N et al. The Task Force on Myocardial Revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Eur Heart J, 2010; 31: 2501-2555.
Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J, 1989; 10: 423-428.
Kjekshus J, Gilpin E, Cali G et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J, 1990; 11: 43-50.
Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin, 2010; 26: 615-629.
Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342: 145-153.
Daly CA, Fox KM, Remme WJ et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J, 2005; 26: 1369-1378.
Anselmino M, Ohrvik J, Ryden L. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart surveyon diabetes and the heart. Eur Heart J, 2010; 31: 3040-3045.
Borer JS, Tardif JC. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol, 2010; 105: 29-35.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ, 2002; 324: 71-86.
Giugliano RP, White JA, Bode C et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med, 2009; 360: 2176-2190.
Valentine N, Van de Laar FA, van Driel ML. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2012; 11: CD005449.
Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet, 2000; 355: 773-778.
Kosiborod M, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation, 2008; 117: 1018-1027.
Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care, 1999; 22: 1827-1831.
Pinto DS, Skolnick AH, Kirtane AJ et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol, 2005; 46: 178-180.
Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J, 2005; 26: 1255-1261.
Kloner RA, Nesto RW. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation, 2008; 117: 2523-2533.
Selker HP, Beshansky JR, Sheehan PR et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA, 2012; 307: 1925-1933.
Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol, 1995; 26: 57-65.
Malmberg K, Ryden L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J, 2005; 26: 650-661.
Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care, 2006; 29: 765-770.
Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ, 1997; 314: 1512-1515.
Malmberg K, Ryden L, Hamsten A et al. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res, 1997; 34: 248-253.
Zhao YT, Weng CL, Chen ML et al. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials. Heart, 2010; 96: 1622-1626.
Fisher M. Impact of hypoglycaemia on coronary artery disease and hypertension. Diabetes Nutr Metab, 2002; 15: 456-459.
Kosiborod M, Inzucchi SE, Goyal A et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA, 2009; 301: 1556-1564.
Mellbin LG, Malmberg K, Waldenstrom A et al. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart, 2009; 95: 721-727.
Alderman EL, Kip KE, Whitlow PL et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol, 2004; 44: 766-774.
Hlatky MA, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, 2009; 373: 1190-1197.
Rana JS, Venkitachalam L, Selzer F et al. Evolution of percutaneous coronary intervention in patients with diabetes: a report from the National Heart, Lung and Blood Institute-sponsored PTCA (1985-1986) and Dynamic (1997-2006) Registries. Diabetes Care, 2010; 33: 1976-1982.
Frye RL, August P, Brooks MM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med, 2009; 360: 2503-2515.
Lagerqvist B, Husted S, Kontny F et al. 5-yearoutcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet, 2006; 368: 998-1004.
Damman P, Hirsch A, Windhausen F et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol, 2010; 55: 858-864.
Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med, 2001; 344: 1879-1887.
Timmer JR, Ottervanger JP, de Boer MJ et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med, 2007; 167: 1353-1359.
Hochman JS, Lamas GA, Buller CE et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med, 2006; 355: 2395-2407.
Kapur A, Hall RJ, Malik IS et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol, 2010; 55: 432-440.
Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009; 360: 961-972.
Banning AP, Westaby S, Morice MC et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol, 2010; 55: 1067-1075.
Kappetein AP, Head SJ, Morice MC et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg, 2013.
Sedlis SP, Morrison DA, Lorin JD et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol, 2002; 40: 1555-1566.
Hannan EL, Wu C, Walford G et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med, 2008; 358: 331-341.
Weintraub WS, Grau-Sepulveda MV, Weiss JM et al. Comparative effectiveness of revascularization strategies. N Eng J Med, 2012; 366: 1467-1476.
Kim WJ, Park DW, Yun SC et al. Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study. JACC Cardiovasc Interv, 2009; 2: 956-963.
Sarno G, Lagerqvist B, Frobert O et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J, 2012; 33: 606-613.
Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, 2012; 379: 1393-1402.
Farkouh ME, Domanski M, Sleeper LA et al. Strategies for multivessel revascularization in patients with diabetes. N Eng J Med, 2012; 367: 2375-2384.
Magnuson EA, Farkouh ME, Fuster V et al. Cost-Effectiveness of Percutaneous Coronary Intervention with Drug Eluting Stents versus Bypass Surgery for Patients with Diabetes and Multivessel Coronary Artery Disease: Results from the FREEDOM Trial. Circulation, 2012.
Sabate M, Jimenez-Quevedo P, Angiolillo DJ et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation, 2005; 112: 2175-2183.
Stettler C, Allemann S, Wandel S et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ, 2008; 337: a1331.
Mulukutla SR, Vlachos HA, Marroquin OC et al. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung and Blood Institute Dynamic Registry. JACC Cardiovasc Interv, 2008; 1: 139-147.
Kereiakes DJ, Cutlip DE, Applegate RJ et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol, 2010; 56: 2084-2089.
Maeng M, Jensen LO, Tilsted HH et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am J Cardiol, 2011; 108: 1232-1237.
Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet, 2006; 367: 569-578.
Ellis SG, Tendera M, de Belder MA et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med, 2008; 358: 2205-2217.
Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA, 2006; 295: 1531-1538.
Puskas JD, Sadiq A, Vassiliades TA et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. Ann Thorac Surg, 2012; 94: 710-715.
Deo SV, Shah IK, Dunlay SM et al. Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients. Ann Thor Surg, 2013; 95: 862-869.
Locker C, Mohr R, Lev-Ran O et al. Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients. Ann Thorac Surg, 2004; 78: 471-475.
Ascione R, Rogers CA, Rajakaruna C, Angelini GD. Inadequate blood glucose control is associated with in-hospital mortality and morbidity in diabetic and nondiabetic patients undergoing cardiac surgery. Circulation, 2008; 118: 113-123.
Mellbin LG, Malmberg K, Norhammar A et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J, 2008; 29: 166-176.
Zeller M, Danchin N, Simon D et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab, 2010; 95: 4993-5002.
Takagi T, Okura H, Kobayashi Y et al. Aprospective,multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv, 2009; 2: 524-531.
Bhamidipati CM, LaPar DJ, Stukenborg GJ et al. Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg, 2011; 141: 543-551.
Chaitman BR, Hardison RM, Adler D et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation, 2009; 120: 2529-2540.
Mack MJ, Banning AP, Serruys PW et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg, 2011; 92: 2140-2146.
Aguilar D, Deswal A, Ramasubbu K et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol, 2010; 105: 373-377.
Seferovic Mitrovic JP, Seferovic PM, Vujisic Tesic B et al. Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2diabetes. Int J Cardiol, 2012; 156: 219-221.
Thrainsdottir IS, Aspelund T, Thorgeirsson G et al. The association between glucose abnormalities and heart failure in the po-pulation-based Reykjavik study. Diabetes Care, 2005; 28: 612-616.
Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care, 2004; 27: 699-703.
Kengne AP, Turnbull F, MacMahon S. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. Prog Cardiovasc Dis, 2010; 53: 45-51.
He J, Ogden LG, Bazzano LA et al. Risk factors for congestive heart failure in US men and women: NHANESI epidemiologic follow-up study. Arch Intern Med, 2001; 161: 996-1002.
Boonman-de Winter LJ, Rutten FH, Cramer MJ et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia, 2012; 55: 2154-2162.
Vaur L, Gueret P, Lievre M et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care, 2003; 26: 855-860.
MacDonald MR, Petrie MC, Hawkins NM et al. Diabetes, left ventricular systolic dysfunction and chronic heart failure. Eur Heart J,2008; 29: 1224-1240.
Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab, 1997; 23: 213-218.
Thrainsdottir IS, Aspelund T, Gudnason V et al. Increasing glucose levels and BMI predict future heart failure experience from the Reykjavik Study. Eur J Heart Fail, 2007; 9: 1051-1057.
Jarnert C, Melcher A, Caidahl K et al. Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes. Eur J Heart Fail, 2008; 10: 1080-1087.
Liu JE, Palmieri V, Roman MJ et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol, 2001; 37: 1943-1949.
Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiog, 2009; 10: 165-193.
McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2012; 33: 1787-1847.
Domanski M, Krause-Steinrauf H, Deedwania P et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol, 2003; 42: 914-922.
Deedwania PC, Giles TD, Klibaner M et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J, 2005; 149: 159-167.
Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation, 2003; 107: 1291-1296.
Gustafsson I, Brendorp B, Seibaek M et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol, 2004; 43: 771-777.
Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARMlow-left ventricular ejection fraction trials. Circulation, 2004; 110: 2618-2626.
Ryden L, Armstrong PW, Cleland JG et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J, 2000; 21: 1967-1978.
Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol, 2003; 41: 1529-1538.
Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 2002; 360: 752-760.
Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003; 349: 1893-1906.
Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003; 362: 772-776.
McMurray JJ, Holman RR, Haffner SM et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010; 362: 1477-1490.
Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J, 2003; 146: 848-853.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 1999; 353: 9-13.
Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001; 344: 1651-1658.
Wlodarczyk JH, Keogh A, Smith K, McCosker C. CHART: congestive cardiac failure in hospitals, an Australian review of treatment. Heart Lung Circ, 2003; 12: 94-102.
Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA, 2000; 283: 1295-1302.
Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003; 362: 7-13.
MacDonald MR, Petrie MC, Fisher M, McMurray JJ. Pharmacologic management of patients with both heart failure and diabetes. Curr Heart Fail Rep, 2009; 6: 126-132.
Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med, 1997; 126: 955-959.
Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA, 1997; 278: 40-43.
Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens, 2005; 18: 731-737.
Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999; 341: 709-717.
Fernandez HM, Leipzig RM. Spironolactone in patients with heart failure. N Engl J Med, 2000; 342: 132.
Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21.
Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, 2010; 376: 875-885.
Dickstein K, Vardas PE, Auricchio A et al. 2010 focused update of ESC Guidelines ondevice therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail, 2010; 12: 1143-1153.
Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005; 352: 225-237.
Mehra MR, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates: 2006. J Heart Lung Transplant, 2006; 25: 1024-1042.
Kilic A, Weiss ES, George TJ et al. What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. Ann Thor Surg, 2012; 93: 699-704.
Gitt AK, Halle M, Hanefeld M et al. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? Eur J Heart Fail, 2012; 14: 1389-1400.
Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ, 2007; 335: 497.
Aguilar D, Chan W, Bozkurt B et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail, 2011; 4: 53-58.
Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure: an observational study. Circulation, 2005; 111: 583-590.
MacDonald MR, Eurich DT, Majumdar SR et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care, 2010; 33: 1213-1218.
Eurich DT, Majumdar SR, McAlister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care, 2005; 28: 2345-2351.
Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 2006; 368: 1096-1105.
Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med, 2007; 357: 28-38.
Sokos GG, Nikolaidis LA, Mankad S et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail, 2006; 12: 694-699.
Swedberg K, Komajda M, Böhm M et al. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?: Findings From the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) Study. 2012. J Am Coll Cardiol, 2012; 59: 1938-1945.
Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001; 285: 2370-2375.
Psaty BM, Manolio TA, Kuller LH et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation, 1997; 96: 2455-2461.
Levy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation, 1999; 99: 3028-3035.
Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-Up Study. Am J Med, 1995; 98: 476-484.
Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 1994; 271: 840-844.
Schnabel RB, Sullivan LM, Levy D et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet, 2009; 373: 739-745.
Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care, 2009; 32: 1851-1856.
Du X, Ninomiya T, de Galan B et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J, 2009; 30: 1128-1135.
Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost, 2008; 99: 295-304.
Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology, 2007; 69: 546-554.
Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010; 31: 2369-2429.
Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Europace, 2012; 14: 1385-1413.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med, 1999; 131: 492-501.
Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006; 367: 1903-1912.
Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 2009; 360: 2066-78.
Connolly SJ, Ezekowitz MD, Yusuf S et al. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011; 364: 806-817.
Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011; 364: 806-817.
Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med, 2011; 365: 981-992.
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med, 2011; 365: 883-891.
Pisters R, Lane DA, Nieuwlaat R et al. Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010; 138: 1093-1100.
Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med, 2001; 345: 1473-1482.
Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J, 2001; 22: 1374-1450.
Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J, 1998; 136: 205-212.
Albert CM, Chae CU, Grodstein F et al. Prospective study of sudden cardiac death among women in the United States. Circulation, 2003; 107: 2096-2101.
Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. Lancet, 1999; 354: 1968-1969.
Curb JD, Rodriguez BL, Burchfiel CM et al. Sudden death, impaired glucose tolerance and diabetes in Japanese American men. Circulation, 1995; 91: 2591-2595.
Jouven X, Lemaitre RN, Rea TD et al. Diabetes, glucose level and risk of sudden cardiac death. Eur Heart J, 2005; 26: 2142-2147.
Kucharska-Newton AM, Couper DJ, Pankow JS et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol, 2010; 47 (suppl. 1): 161-168.
MacDonald MR, Petrie MC, Varyani F et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J, 2008; 29: 1377-1385.
Junttila MJ, Barthel P, Myerburg RJ et al. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. Heart Rhythm, 2010; 7: 1396-1403.
Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006; 114: e385-e484.
O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med, 1991; 79: 495-502.
Forsen A, Kangro M, Sterner G et al. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. Diabet Med, 2004; 21: 852-858.
Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest, 2004; 27: 175-181.
Rozanski GJ, Xu Z. A metabolic mechanism for cardiac K+ channel remodelling. Clin Exp Pharmacol Physiol, 2002; 29: 132-137.
Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. The Quarterly Journal of Medicine, 1980; 49: 95-108.
Gerritsen J, Dekker JM, Ten Voorde BJ et al. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia, 2000; 43: 561-570.
Ewing DJ, Boland O, Neilson JM et al. Autonomic neuropathy, QT interval lengthening and unexpected deaths in male diabetic patients. Diabetologia, 1991; 34: 182-185.
Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes: the 'dead in bed' syndrome revisited. Diabetologia, 2009; 52: 42-45.
Singh JP, Larson MG, O'Donnell CJ et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol, 2000; 86: 309-312.
Valensi P, Extramiana F, Lange C et al. Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study. Diabet Med, 2011; 28: 440-449.
Schroeder EB, Chambless LE, Liao D et al. Diabetes, glucose, insulin and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care, 2005; 28: 668-674.
Barthel P, Bauer A, Muller A et al. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care, 2011; 34: 1833-1837.
Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 2003; 26: 1895-1901.
Suarez GA, Clark VM, Norell JE et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry, 2005; 76: 240-245.
Ziegler D, Zentai CP, Perz S et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care, 2008; 31: 556-561.
Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 2851-2906.
Fowkes FG, Housley E, Riemersma RA et al. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol, 1992; 135: 331-340.
Bots ML, Breslau PJ, Briet E et al. Cardiovascular determinants of carotid artery disease. The Rotterdam Elderly Study. Hypertension, 1992; 19: 717-720.
Mathiesen EB, Joakimsen O, Bonaa KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromso Study. Cerebrovasc Dis, 2001; 12: 44-51.
O'Leary DH, Polak JF, Kronmal RA et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke, 1992; 23: 1752-1760.
Ferrieres J, Cambou JP, Gayet JL et al. Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hospital setting. Int J Cardiol, 2006; 112: 302-307.
Alberts MJ, Bhatt DL, Mas JL et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J, 2009; 30: 2318-2326.
Hobbs SD, Bradbury AW. Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur J Vasc Endovasc Surg, 2003; 26: 341-347.
Leal J, Gray AM, Clarke PM. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J, 2009; 30: 834-839.
Campbell WB, Ponette D, Sugiono M. Long-term results following operation for diabetic foot problems: arterial disease confers a poor prognosis. Eur J Vasc Endovasc Surg, 2000; 19: 174-177.
Stettler C, Allemann S, Juni P et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J, 2006; 152: 27-38.
Diehm C, Allenberg JR, Pittrow D et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation, 2009; 120: 2053-2061.
Mensah GA, Brown DW, Croft JB, Greenlund KJ. Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). Am J Prev Med, 2005; 29: 68-74.
de L II, Hoeks SE, van Gestel YR et al. The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease. Eur J Vasc Endovasc Surg, 2009; 38: 482-487.
Ashworth NL, Chad KE, Harrison EL et al. Homeversus center based physical activity programs in older adults. Cochrane Database Syst Rev, 2005; 1: CD004017.
Momsen AH, Jensen MB, Norager CB et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg, 2009; 38: 463-474.
Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med, 1991; 151: 1769-1776.
Aronow WS, Ahn C. Effect of beta blockers on incidence of newcoronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol, 2001; 87: 1284-1286.
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007; 45: 645-654.
Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med, 2007; 261: 276-284.
Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: Part II. Circulation, 2003; 108: 1655-1661.
Lepantalo M, Apelqvist J, Setacci C et al. Chapter V: Diabetic foot. Eur J Vasc Endovasc Surg, 2011; 42: S60-S74.
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA, 1979; 241: 2035-2038.
Giorda CB, Avogaro A, Maggini M et al. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke, 2007; 38: 1154-1160.
Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke, 2001; 32: 2559-2566.
Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet, 1998; 351: 1379-1387.
Barnett HJ, Taylor DW, Eliasziw M et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med, 1998; 339: 1415-1425.
Rothwell PM, Giles MF, Flossmann E et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet, 2005; 366: 29-36.
Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med, 1984; 310: 356-360.
Ninomiya T, Perkovic V, de Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol, 2009; 20: 1813-1821.
Klein R, Klein BE. Are individuals with diabetes seeing better?: a long-term epidemiological perspective. Diabetes, 2010; 59: 1853-1860.
Klein R, Knudtson MD, Lee KE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology, 2009; 116: 497-503.
Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care, 2009; 32: 2307-2313.
Gerstein HC, Ambrosius WT, Danis R et al. Diabetic Retinopathy, its Progression and Incident Cardiovascular Events in the ACCORD Trial. Diabetes Care, 2012.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res, 2010; 107: 1058-1070.
de Boer IH, Rue TC, Cleary PA et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med, 2011; 171: 412-420.
Beulens JW, Patel A, Vingerling JR et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia, 2009; 52: 2027-2036.
Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010; 363: 233-244.
Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet, 2010; 376: 419-430.
The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol, 1995; 113: 36-51.
Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med, 2009; 151: 11-20, W3-4.
Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med, 2009; 361: 40-51.
Penno G, Chaturvedi N, Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes, 1998; 47: 1507-1511.
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med, 2001; 134: 370-379.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med, 1993; 329: 1456-1462.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart utcomes Prevention Evaluation Study Investigators. Lancet, 2000; 355: 253-259.
Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001; 345: 861-869.
Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001; 345: 851-860.
Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet, 2008; 372: 1385-1393.
Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet, 2008; 372: 1394-1402.
Herz M, Gaspari F, Perico N et al. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol, 2011; 151: 136-142.
Davis TM, Ting R, Best JD et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 2011; 54: 280-290.
Silva PS, Cavallerano JD, Sun JK et al. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol, 2010; 6: 494-508.
Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med, 2009; 361: 2019-2032.
Fong DS, Aiello L, Gardner TW et al. Diabetic retinopathy. Diabetes Care, 2003; 26: 226-229.
Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, 2010; 33: 2399-2405.
Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 2011; 118: 615-625.
Lewin SA, Skea ZC, Entwistle V et al. Interventions for providers to promote a patient-centred approach in clinical consultations. Cochrane Database Syst Rev, 2001; 4: CD003267.
Deakin T, McShane CE, Cade JE, Williams RD. Group based training for selfmanagement strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev, 2005; 2: CD003417.
Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003; 26: 3230-3236.
Wood DA, Kotseva K, Connolly S et al. Nurse-coordinatedmultidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet, 2008; 371: 1999-2012.
Tierney S, Mamas M, Woods S et al. What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies. Heart Fail Rev, 2012; 17: 107-115.
Haynes RB, Ackloo E, Sahota N et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev, 2008; 2: CD000011.
van Dulmen S, Sluijs E, van Dijk L et al. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res, 2007; 7: 55.
Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract, 2005; 55 : 305-312.
Aschner P, LaSalle J, McGill M. The team approach to diabetes management: partnering with patients. Int J Clin Pract Suppl, 2007; 157: 22-30.
McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol, 2004; 44: 810-819.
Allen JK, Dennison CR. Randomized trials of nursing interventions for secondary prevention in patients with coronary artery disease and heart failure: systematic review. J Cardiovasc Nurs, 2010; 25: 207-220.
Berra K. Does Nurse Case Management Improve Implementation of Guidelines for Cardiovascular Disease Risk Reduction? J Cardiovasc Nurs, 2011; 26: 145-167.
